RESUMEN
Postpartum depression is one of the most common complications of childbirth. Untreated postpartum depression can have substantial adverse effects on the well-being of the mother and child, negatively impacting child cognitive, behavioral, and emotional development with lasting consequences. There are a number of therapeutic interventions for postpartum depression including pharmacotherapy, psychotherapy, neuromodulation, and hormonal therapy among others, most of which have been adapted from the treatment of major depressive disorder outside of the peripartum period. Current evidence of antidepressant treatment for postpartum depression is limited by the small number of randomized clinical trials, underpowered samples, and the lack of long-term follow-up. The peripartum period is characterized by rapid and significant physiological change in plasma levels of endocrine hormones, peptides, and neuroactive steroids. Evidence supporting the role of neuroactive steroids and γ-aminobutyric acid (GABA) in the pathophysiology of postpartum depression led to the investigation of synthetic neuroactive steroids and their analogs as potential treatment for postpartum depression. Brexanolone, a soluble proprietary intravenous preparation of synthetic allopregnanolone, has been developed. A recent series of open-label and placebo-controlled randomized clinical trials of brexanolone in postpartum depression demonstrated a rapid reduction in depressive symptoms, and has led to the submission for regulatory approval to the US Food and Drug Administration (decision due in March 2019). SAGE-217, an allopregnanolone analog, with oral bioavailability, was recently tested in a randomized, double-blind, placebo-controlled phase III study in severe postpartum depression, with reportedly positive results. Finally, a 3ß-methylated synthetic analog of allopregnanolone, ganaxolone, is being tested in both intravenous and oral forms, in randomized, double-blind, placebo-controlled phase II studies in severe postpartum depression.
Asunto(s)
Depresión Posparto/tratamiento farmacológico , Desarrollo de Medicamentos , Moduladores del GABA/uso terapéutico , Neuroesteroides/uso terapéutico , Pregnanos/uso terapéutico , Pregnanolona/uso terapéutico , Pirazoles/uso terapéutico , beta-Ciclodextrinas/uso terapéutico , Animales , Depresión Posparto/epidemiología , Depresión Posparto/metabolismo , Combinación de Medicamentos , Femenino , Moduladores del GABA/administración & dosificación , Moduladores del GABA/efectos adversos , Humanos , Neuroesteroides/administración & dosificación , Neuroesteroides/efectos adversos , Pregnanos/administración & dosificación , Pregnanos/efectos adversos , Pregnanolona/administración & dosificación , Pregnanolona/efectos adversos , Pirazoles/administración & dosificación , Pirazoles/efectos adversos , Ensayos Clínicos Controlados Aleatorios como Asunto , Estados Unidos , United States Food and Drug Administration , beta-Ciclodextrinas/administración & dosificación , beta-Ciclodextrinas/efectos adversosRESUMEN
Pregnane glycosides appear to modulate food intake by possibly affecting the hypothalamic feeding circuits; however, the mechanisms of the appetite-regulating effect of pregnane glycosides remain obscure. Here, we show that pregnane glycoside-enriched extracts from swamp milkweed Asclepias incarnata at 25-100 mg/kg daily attenuated food intake (up to 47.1 ± 8.5% less than controls) and body weight gain in rats (10% for males and 9% for females, respectively) by activating melanocortin signaling and inhibiting gastric emptying. The major milkweed pregnane glycoside, ikemagenin, exerted its appetite-regulating effect by decreasing levels of agouti-related protein (0.6-fold) but not NPY satiety peptides. Ikemagenin treatment also increased secretion of brain-derived neurotropic factor (BDNF) downstream of melanocortin receptors in the hypothalamus (1.4-fold) and in the C6 rat glioma cell culture in vitro (up to 6-fold). These results support the multimodal effects of pregnane glycosides on feeding regulation, which depends on the activity of the melanocortin signaling pathway and BDNF.
Asunto(s)
Asclepias/química , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Ingestión de Alimentos/efectos de los fármacos , Glicósidos/administración & dosificación , Melanocortinas/metabolismo , Extractos Vegetales/administración & dosificación , Pregnanos/administración & dosificación , Animales , Apetito/efectos de los fármacos , Factor Neurotrófico Derivado del Encéfalo/genética , Línea Celular Tumoral , Femenino , Humanos , Masculino , Modelos Animales , Ratas , Ratas WistarRESUMEN
We previously reported that seven pregnane glycosides including cynatroside B isolated from the roots of Cynanchum atratum significantly inhibited acetylcholinesterase (AChE) activity. In the present study, we have characterized the mode of AChE inhibition of cynatroside B, the most potent of these isolated pregnane glycoside inhibitors. We have also examined the anti-amnesic activity of cynatroside B. Cynatroside B inhibited AChE activity in a dose-dependent manner and its IC50 value was 3.6 microM. The mode of AChE inhibition by cynatroside B was reversible and non-competitive in nature. Moreover, cynatroside B (1.0 mg/kg body weight i.p.) significantly ameliorated memory impairments induced in mice by scopolamine (1.0 mg/kg body weight s.c.) as measured in the passive avoidance and the Morris water maze tests. We suggest, therefore, that cynatroside B has both anti-AChE and anti-amnesic activities that may ultimately hold significant therapeutic value in alleviating certain memory impairments observed in Alzheimer's disease.